Lau 2021 — Once-weekly Cagrilintide Weight Management Phase 2

The Lancet·November 1, 2021

David C. W. Lau, Lars Erichsen, Ana M. Francisco, Rachel L. Batterham

Summary

Cagrilintide produced dose-dependent body-weight reductions and was generally well tolerated, supporting amylin-analog development for weight management.

Study Details

Study Design

Multicentre randomized double-blind placebo-controlled and active-controlled dose-finding phase 2 trial

Indication

Overweight or obesity

Intervention

Once-weekly cagrilintide 0.3–4.5 mg vs placebo and liraglutide comparator

Species

Human

Sample Size

706 subjects

Risk of Bias Assessment

Sponsor-funded